High-Performance LC-Based "Well-Characterized Biologics"

Skip to Navigation


  • Date: Mar 9, 2011 - 15:00 - 16:00 (local time)
  • Categories: HPLC
thumbnail image: High-Performance LC-Based

Latest separationsNOW

Sponsored by:
Agilent Technologies

High-Performance LC-Based
'Well-Characterized Biologics'

This webinar summarizes the highlights of the Agilent 1200 Infinity platform to efficiently address the current limitations of productivity, resolution and unspecific binding for New Biological Entities or 'NBEs', including the special aspects of compliance in regulatory environments.

This webinar has been recorded and is available on-demand.

Register now >>>

Agilent 1200Different LC-based techniques are applied to characterise biotherapeutics, or to prove protein identity, in order to fulfill complex regulatory requirements.

Commonly, LC techniques are used to characterise NBEs: ion-exchange chromatography to demonstrate charge profiles, size-exclusion chromatography to show the absence of aggregation and reversed phase separations to provide evidence for protein sequence identity.

For large bio-molecules, all these techniques share the limitation that analyses are very time consuming. In addition, they may lack resolution, and unspecified interactions can occur between the instrument and column surfaces.

UHPLC on the 1260 bio-inert LC instrument, in combination with small particle columns technology, is an efficient approach to increase productivity and resolution: not only for small molecules, but also for peptides and proteins.

This webinar has been recorded and is now available on-demand.

  • Already registered? Please login using the link in your confirmation emails...
  • Register now >>>

Your Speakers

Dr. Vollmer
Dr. Martin Vollmer
Product Manager,
Bio-inert LC,
Agilent Technologies
Dr. Lloyd
Dr. Linda L Lloyd
Product Manager,
Bio-HPLC Columns,
Agilent Technologies
Dr. Huber
Dr. Ludwig Huber
Chief Advisor,
Global FDA Compliance,
Dr. Martin Vollmer: Biography

Dr. Martin Vollmer is a Product Manager at Agilent Technologies. He is responsible for global Bio-inert LC, SFC and LC autosampler product marketing activities. Martin has been involved in Agilent R&D with low flow LC and HPLC chip development for 7 years, prior to joining the Agilent Marketing team 2 years ago. He has a Ph.D. from University of Stuttgart, conducting research on recombinant catalytic proteins.
Dr. Linda Lloyd: Biography

Dr. Linda Lloyd is the BioColumns HPLC Product Manager at Agilent Technologies. She is responsible for global product marketing activities for the Agilent BioHPLC columns. Linda came to Agilent through the acquisition of Varian / Polymer Laboratories, where she was involved in biomolecule analysis and purification and the development of new HPLC materials and methodologies for biomolecule separations.
Dr. Ludwig Huber: Biography

Dr. Ludwig Huber is chief advisor for global FDA compliance to Agilent Technologies. He has published more than 100 papers on validation and compliance and is the author of the several books including "Validation of Computerized Analytical and Networked Systems", and "Validation and Qualification in Analytical Laboratories". He is also the author and editor of www.labcompliance.com, the global on-line resources for validation and compliance in laboratories. Dr. Huber is on the Scientific Advisory board of IVT's GxP and Validation Journals, and he has given multiple presentations mainly on GLP/GMP, 21 CFR Part 11 and Validation around the world. This included seminars and presentations for the US FDA, PIC/S and several national health agencies.

Click here to register now >>>

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in spectroscopy? Visit our sister site spectroscopyNOW.com

Copyright © 2019 John Wiley & Sons, Inc. All Rights Reserved